This review briefly summarises pharmacological and clinical characteristics of fentanyl citrate, in two rapid-onset transmucosal formulations, that are relevant in the context of treating breakthrough cancer-related pain.
Independent commentary has been provided by Dr Maria Cigolini, Clinical Head, Department of Palliative Medicine Royal Prince Alfred Hospital, Camperdown, NSW, Clinical Lecturer, University of Sydney.
Please login below to download this issue (PDF)